TransMedics raised its 2026 revenue guidance to a range of $764 million to $774 million following strong performance and record results in the third quarter ended September 30. The results exceeded analyst expectations, and the company’s shares jumped 14.4% on November 6. TransMedics also shifted the ENHANCE Part B and DENOVO catalysts to early 2027.
The company posted record quarterly revenue, but net income and operating margin fell from a year earlier amid planned investment and service expansion.
Read the full storyThe higher outlook came as service and product revenue increased, while net income and operating margin declined from the same period last year.
The forecast increase came as transport services expanded and heart and liver transplant volumes grew, while net income fell to $17.1 million from $24.3 million a year earlier.